- Home
- NG vs SNDX Comparison
NG vs SNDX Comparison
Compare NG & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NG
- SNDX
- Stock Information
- Founded
- NG 1984
- SNDX 2005
- Country
- NG Canada
- SNDX United States
- Employees
- NG 13
- SNDX N/A
- Industry
- NG Precious Metals
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- NG Basic Materials
- SNDX Health Care
- Exchange
- NG Nasdaq
- SNDX Nasdaq
- Market Cap
- NG 1.1B
- SNDX 1.2B
- IPO Year
- NG N/A
- SNDX 2016
- Fundamental
- Price
- NG $3.22
- SNDX $14.34
- Analyst Decision
- NG
- SNDX Strong Buy
- Analyst Count
- NG 0
- SNDX 10
- Target Price
- NG N/A
- SNDX $36.20
- AVG Volume (30 Days)
- NG 2.0M
- SNDX 2.1M
- Earning Date
- NG 01-23-2025
- SNDX 02-25-2025
- Dividend Yield
- NG N/A
- SNDX N/A
- EPS Growth
- NG N/A
- SNDX N/A
- EPS
- NG N/A
- SNDX N/A
- Revenue
- NG N/A
- SNDX $16,000,000.00
- Revenue This Year
- NG N/A
- SNDX N/A
- Revenue Next Year
- NG N/A
- SNDX N/A
- P/E Ratio
- NG N/A
- SNDX N/A
- Revenue Growth
- NG N/A
- SNDX N/A
- 52 Week Low
- NG $2.23
- SNDX $12.06
- 52 Week High
- NG $4.88
- SNDX $25.34
- Technical
- Relative Strength Index (RSI)
- NG 48.42
- SNDX 54.69
- Support Level
- NG $3.07
- SNDX $13.97
- Resistance Level
- NG $3.26
- SNDX $13.16
- Average True Range (ATR)
- NG 0.15
- SNDX 0.66
- MACD
- NG 0.01
- SNDX 0.17
- Stochastic Oscillator
- NG 67.31
- SNDX 85.39
About NG Novagold Resources Inc.
Novagold Resources Inc is a mineral exploration company engaged in the exploration and development of mineral properties. The company owns 50% of the Donlin Gold project, which is located in southwestern Alaska, approximately 20 kilometers north of the village of Crooked Creek on the Kuskokwim River.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.